INTRODUCTION
Aspergillus fumigatus is a ubiquitous, globally distributed ascomycete fungus with an ecological niche of decaying vegetation and soil (
1). In recent years, questions regarding the ecology and evolution of
A. fumigatus, motivated primarily by the organism's ability to infect immunocompromised hosts but also by the emergence of antifungal drug resistance, have been raised (
2–4).
A. fumigatus is an opportunistic pathogen causing a spectrum of respiratory illnesses, from asthma-like symptoms to invasive aspergillosis (IA), where mortality rates of 40 to 90% have been reported in immunocompromised patients (
5–7). There is a limited arsenal of drugs available for the treatment and prophylaxis of
A. fumigatus-related aspergillosis, with the azole antifungals itraconazole, posaconazole, and voriconazole acting as the frontline defense against this disease (
8).
Predictably, resistance to azole antifungals has emerged, and in recent years there have been increasing reports of resistant
A. fumigatus isolates recovered from patients with aspergillosis (
9). Resistance to azole antifungals can evolve during azole therapy (
10–12); however, the extensive use of agricultural azole compounds in the environment for crop protection has now been linked to the emergence of azole resistance in
A. fumigatus populations (
4,
13–16). The most commonly occurring mechanisms of azole resistance are alterations in
cyp51A (
erg11), the gene encoding sterol 14-demethylase (cytochrome P450 51A [CYP51A]), which is the target protein of azole antifungals (
17–19). In
A. fumigatus, resistance is most frequently caused by a tandem repeat (TR) in the promoter that is linked to single nucleotide polymorphisms (SNPs) in the coding sequence, exemplified by the widespread occurrence of two alleles, TR
34/L98H and TR
46/Y121F/T289A (
9,
20). The most frequently observed genotype, TR
34/L98H, consists of a 34-nucleotide tandem repeat (TR
34) in the
cyp51A promoter that upregulates mRNA expression and a leucine-to-histidine substitution in the coding sequence that most likely affects the interaction between the azole ligand and the protein heme cofactor (
21–23). The less frequent but emerging genotype, TR
46/Y121F/T289A, is also known to have elevated mRNA expression, and it has been shown that TR
46 in association with two SNPs (Y121F/T289A) confers high levels of resistance to azoles, including voriconazole (
24).
Delineating the genetic diversity and evolutionary life history of pathogenic fungi can help elucidate the epidemiology of infection, aid in the prophylaxis and treatment of the disease-causing pathogen, and further our understanding of antifungal resistance evolution (
25). Multiple studies conducted in the past 30 years have used a range of molecular markers to help unravel the population genetics of
A. fumigatus (
14,
26–31). Findings have ranged from no genetic structure to multiple distinct clusters, with varying reproducibility being found across methodologies. One commonly recurring feature nonetheless has been the identification of two well-supported phylogenetic clades (
9,
29,
32–35). Preliminary studies utilizing high-resolution whole-genome sequencing found that isolates harboring TR
34/L98H were not randomly distributed across the phylogeny and that the two-clade population structure could be the result of azole-resistant genotypes perturbing the natural population structure of
A. fumigatus via selective sweeps (
9,
32).
Despite this, little is still known about the global distribution of azole resistance across the wider
A. fumigatus metapopulation and the genetic relationships between azole-resistant isolates recovered from the environment and patients (
36). Here, we amend these gaps in our knowledge by analyzing the genetic relatedness of a collection of 4,049
A. fumigatus isolates sampled worldwide and genotyped at 9 microsatellite loci within the context of the resistance genotypes TR
34/L98H and TR
46/Y121F/T289A. The methodology used in this study forms the basis of a user-friendly bioinformatic tool, AfumID, for clinicians and researchers to genetically characterize novel
A. fumigatus isolates within the context of the wider population genetic structure of this fungus.
DISCUSSION
In recent years, the population genetic structure of
Aspergillus fumigatus has been well studied by utilizing a range of molecular markers to elucidate the genetic diversity and life history of this ubiquitous human fungal pathogen (
9,
26–29,
32,
33,
35). Nevertheless, our understanding of the emergence of azole antifungal resistance and the effect that this has had on the genetic diversity of contemporary
A. fumigatus populations remains understudied. Here, we addressed these gaps in our knowledge by exploiting the vast global STR
Af collection held at the Centre of Expertise in Mycology, Radboudumc/Canisius-Wilhelmina Ziekenhuis (CWZ), in Nijmegen, The Netherlands. First, we show that the collection of 4,049
A. fumigatus strains can be clustered into two broadly defined populations and that two known resistance genotypes, TR
34/L98H and TR
46/Y121F/T289A, are unevenly distributed across these two populations. Second, resistant isolates harboring either TR
34/L98H or TR
46/Y121F/T289A are genetically depauperate compared to the wild types. Third, resistant clones are globally distributed and found in both environmental and clinical settings. Finally, we present AfumID, an R Shiny application that allows users to easily explore the genetic relationship of novel STR
Af genotypes in relation to the full STR
Af data set.
There has never been a definitive answer to the population differentiation of
A. fumigatus, with multiple studies reporting a range of optimal population subdivisions (
9,
26,
28,
29,
32). Here, we have shown that although there is no apparent clustering with regard to raw Bruvo’s distances, when isolates are hierarchically clustered using Ward’s method, which minimizes the total within-cluster variance and maximizes the between-cluster variance, two broad clades are found. Differentiation of these two clades was reinforced by a modified DAPC analysis, which revealed a detectable difference in allele frequencies when populations were discriminated by prior hierarchical clustering. Studies exploiting multilocus sequence typing or genomic sequencing have similarly revealed the presence of a biclade population structure (
9,
29,
32,
35), further substantiating our findings and advocating a robust deviation from panmixia. Moreover, our demonstration of the nonrandom distribution of resistance genotypes TR
34/L98H and TR
46/Y121F/T289A across the two populations suggests a genetic component restricting the resistance genotype to one of the two populations. Sexual crossing both within and between populations may provide more insight into the potential for gene flow across the metapopulation and the propensity for introgression of resistant alleles (
36,
37).
The genetic background of isolates harboring either TR
34/L98H or TR
46/Y121F/T289A was less diverse than that of the nonresistant, wild-type isolates. All four indices exhibited a significant reduction in diversity, revealing a pattern consistent with the rapid selection of beneficial mutations and the clonal expansion of isolates with highly fit resistance genotypes (
38). Recent genomic studies have observed an expansion of the TR
34/L98H genotype in India (
32,
39), and according to our findings, it would appear that this situation may be a common occurrence worldwide. Indeed, it is apparent that identical clonal
A. fumigatus isolates harboring TR
34/L98H and TR
46/Y121F/T289A occur globally, evidence that large geographic distances are not a barrier to the potential distribution of this species. This further supports the idea that
A. fumigatus is a truly global fungus with the potential to migrate across vast areas of land and sea by virtue of both environmental (passive) and anthropogenic (active) dispersal (
26). Numerous country-based studies have now identified clinical and environmental azole-resistant isolates harboring the two main resistance genotypes (
40), and many have been incorporated into the STR
Af database used in this study. However, until now, understanding the relationship between these isolates was limited (
26). Here, we distinctly show that many azole-resistant isolates with identical microsatellite profiles occur worldwide and present a globally important threat to the use and stewardship of this important class of drugs (
3).
Our study has also shown there to a be recurrent relationship between environmental and clinical isolates. On multiple occasions, we have shown that azole-resistant
A. fumigatus clones sharing the exact same STR
Af genotype were sourced from both environmental and clinical locations, a pattern that we also show to be vanishingly unlikely to occur by chance alone. This finding strengthens previous research that has shown similar results (
34,
41,
42). Moreover, considering our current understanding that
A. fumigatus conidia are unlikely to be transferred from patient to patient and are therefore unlikely to transfer from patient to the environment, it is highly likely that isolates harboring either TR
34/L98H or TR
46/Y121F/T289A have been acquired from environmental sources (
43).
Antifungal resistance is increasingly a global problem in both agricultural and health care settings, and the evolution of azole resistance in
A. fumigatus presents a worrisome contribution to this precarious situation (
2,
44). Understanding the manner by which way azole resistance alleles are being distributed both genetically and spatially will greatly enhance our knowledge of the evolution of resistance and may help to engineer a response to the continued emergence of aspergillosis. By incorporating our analysis into a user-friendly application, we have provided clinicians and researchers with a method for the fast, automated characterization of
A. fumigatus isolates that will inform the epidemiological study of patients’ infections and inform drug stewardship decisions in health care settings for this increasingly important pathogen.
ACKNOWLEDGMENTS
We thank Ali Abdolrasouli, Darius Armstrong-James, Jennifer Shelton, Kieran Bates, and Zhian Kamvar for their helpful discussions while analyzing the data. We also thank Hanneke de Valk, Corina Bens, and Theun de Groot for curation of the STRAf database.
T.R.S., J.R., M.C.F., and T.J. were supported by the Natural Environmental Research Council (NERC; NE/P001165/1) and the Medical Research Council (MRC; MR/R015600/1). We acknowledge joint-center funding from the UK Medical Research Council and Department for International Development. J.F.M. is financially supported by the Canisius Wilhelmina Research Support Fund.
T.R.S., J.R., M.C.F. and T.J. conceived and designed the study. F.H. and J.F.M. provided the data. T.R.S., J.Z. and T.J. analyzed the data. T.R.S. wrote the manuscript. T.R.S., J.Z., J.R., F.H., J.F.M., M.C.F. and T.J. discussed the results and commented on the manuscript.